Trial Outcomes & Findings for Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate (NCT NCT00577720)

NCT ID: NCT00577720

Last Updated: 2012-01-13

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

181 participants

Primary outcome timeframe

Baseline and Week 13

Results posted on

2012-01-13

Participant Flow

Screening began 14-Jul-2006

Participant milestones

Participant milestones
Measure
35 mg IRBB (Immediate Release Before Breakfast)
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Overall Study
STARTED
37
36
36
72
Overall Study
ITT (Intent to Treat) Population
34
35
35
65
Overall Study
COMPLETED
33
35
35
65
Overall Study
NOT COMPLETED
4
1
1
7

Reasons for withdrawal

Reasons for withdrawal
Measure
35 mg IRBB (Immediate Release Before Breakfast)
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Overall Study
Adverse Event
2
1
0
4
Overall Study
Lost to Follow-up
0
0
1
0
Overall Study
Protocol Violation
0
0
0
1
Overall Study
Withdrawal by Subject
2
0
0
2

Baseline Characteristics

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=37 Participants
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=36 Participants
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=36 Participants
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=72 Participants
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Total
n=181 Participants
Total of all reporting groups
Age Continuous
61.1 years
STANDARD_DEVIATION 6.2 • n=5 Participants
58.9 years
STANDARD_DEVIATION 6.7 • n=7 Participants
60.0 years
STANDARD_DEVIATION 6.1 • n=5 Participants
59.7 years
STANDARD_DEVIATION 7.8 • n=4 Participants
59.9 years
STANDARD_DEVIATION 7.0 • n=21 Participants
Sex: Female, Male
Female
37 Participants
n=5 Participants
36 Participants
n=7 Participants
36 Participants
n=5 Participants
72 Participants
n=4 Participants
181 Participants
n=21 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
13 Participants
n=5 Participants
9 Participants
n=7 Participants
14 Participants
n=5 Participants
23 Participants
n=4 Participants
59 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=5 Participants
27 Participants
n=7 Participants
22 Participants
n=5 Participants
49 Participants
n=4 Participants
122 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
Race/Ethnicity, Customized
Asian (Oriental)
6 Participants
n=5 Participants
6 Participants
n=7 Participants
3 Participants
n=5 Participants
10 Participants
n=4 Participants
25 Participants
n=21 Participants
Race/Ethnicity, Customized
Black
0 Participants
n=5 Participants
1 Participants
n=7 Participants
3 Participants
n=5 Participants
2 Participants
n=4 Participants
6 Participants
n=21 Participants
Race/Ethnicity, Customized
Caucasian
30 Participants
n=5 Participants
29 Participants
n=7 Participants
26 Participants
n=5 Participants
56 Participants
n=4 Participants
141 Participants
n=21 Participants
Race/Ethnicity, Customized
Multi-Racial
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
1 Participants
n=4 Participants
1 Participants
n=21 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=5 Participants
0 Participants
n=7 Participants
4 Participants
n=5 Participants
2 Participants
n=4 Participants
7 Participants
n=21 Participants
Race/Ethnicity, Customized
Hawaiian/Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
1 Participants
n=4 Participants
1 Participants
n=21 Participants
Region of Enrollment
United States
37 participants
n=5 Participants
36 participants
n=7 Participants
36 participants
n=5 Participants
72 participants
n=4 Participants
181 participants
n=21 Participants

PRIMARY outcome

Timeframe: Baseline and Week 13

Population: ITT Population

Outcome measures

Outcome measures
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=34 Participants
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=35 Participants
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=35 Participants
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=65 Participants
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Percent Change in Serum CTX (Type I Collagen C-telopeptide), ITT (Intent to Treat) Population
-43.20 Percent Change
Interval -55.83 to -30.58
-62.08 Percent Change
Interval -73.59 to -50.56
-65.11 Percent Change
Interval -77.7 to -52.52
-66.30 Percent Change
Interval -77.42 to -55.18

SECONDARY outcome

Timeframe: Baseline and Week 13

Population: ITT Population

Outcome measures

Outcome measures
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=34 Participants
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=35 Participants
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=35 Participants
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=65 Participants
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Percent Change in Urine NTX/Cr (Urine Type I Collagen Cross-linked N-telopeptide Corrected for Creatinine Clearance), ITT Population
-38.57 Percent Change
Interval -56.6 to -20.54
-46.60 Percent Change
Interval -63.04 to -30.17
-43.65 Percent Change
Interval -61.62 to -25.67
-54.27 Percent Change
Interval -70.14 to -38.4

SECONDARY outcome

Timeframe: Baseline and Week 13

Population: ITT Population

Outcome measures

Outcome measures
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=34 Participants
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=35 Participants
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=35 Participants
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=65 Participants
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Percent Change in Serum BAP (Bone-specific Alkaline Phosphatase), ITT Population
-10.99 Percent Change
Interval -19.62 to -2.365
-10.41 Percent Change
Interval -18.28 to -2.545
-20.00 Percent Change
Interval -28.6 to -11.4
-17.36 Percent Change
Interval -24.96 to -9.767

Adverse Events

35 mg IRBB (Immediate Release Before Breakfast)

Serious events: 0 serious events
Other events: 27 other events
Deaths: 0 deaths

35 mg DRFB (Delayed Release Following Breakfast)

Serious events: 1 serious events
Other events: 19 other events
Deaths: 0 deaths

50 mg DRFB

Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths

50 mg DRBB (Delayed Release Before Breakfast)

Serious events: 1 serious events
Other events: 51 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=37 participants at risk
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=36 participants at risk
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=36 participants at risk
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=72 participants at risk
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Infections and infestations
Appendicitis
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
General disorders
Chest Pain
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Hepatobiliary disorders
Cholelithiasis
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007

Other adverse events

Other adverse events
Measure
35 mg IRBB (Immediate Release Before Breakfast)
n=37 participants at risk
35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
35 mg DRFB (Delayed Release Following Breakfast)
n=36 participants at risk
35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRFB
n=36 participants at risk
50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
50 mg DRBB (Delayed Release Before Breakfast)
n=72 participants at risk
50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
Musculoskeletal and connective tissue disorders
Back Pain
8.1%
3/37 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
11.1%
4/36 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
4.2%
3/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
5.4%
2/37 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
4.2%
3/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Pain in Extremity
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
4.2%
3/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Neck Pain
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Musculoskeletal Chest Pain
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Musculoskeletal Stiffness
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Arthralgia
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
6.9%
5/72 • Number of events 7 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Muscle Spasms
2.7%
1/37 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Exostosis
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Bone Pain
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Pain in Jaw
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Myalgia
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
4.2%
3/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Musculoskeletal and connective tissue disorders
Groin Pain
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Abdominal Pain Upper
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
8.3%
3/36 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
11.1%
8/72 • Number of events 11 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Abdominal Pain
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
8.3%
6/72 • Number of events 9 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Abdominal Tenderness
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Dyspepsia
10.8%
4/37 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
5.6%
4/72 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Eructation
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Nausea
8.1%
3/37 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
11.1%
4/36 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
12.5%
9/72 • Number of events 13 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Vomiting
5.4%
2/37 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
8.3%
3/36 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Toothache
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Diarrhoea
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
16.7%
6/36 • Number of events 6 • 14 Jul 2006 thru 27 Jan 2007
9.7%
7/72 • Number of events 14 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Abdominal Distension
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Flatulence
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 5 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Constipation
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
5.6%
2/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Gastrooesophageal Reflux Disease
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Stomach Discomfort
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 4 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Rectal Haemorrhage
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Gastrointestinal disorders
Haematochezia
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Nervous system disorders
Headache
18.9%
7/37 • Number of events 9 • 14 Jul 2006 thru 27 Jan 2007
22.2%
8/36 • Number of events 11 • 14 Jul 2006 thru 27 Jan 2007
27.8%
10/36 • Number of events 10 • 14 Jul 2006 thru 27 Jan 2007
22.2%
16/72 • Number of events 26 • 14 Jul 2006 thru 27 Jan 2007
Nervous system disorders
Sinus Headache
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Nervous system disorders
Somnolence
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 10 • 14 Jul 2006 thru 27 Jan 2007
Nervous system disorders
Dizziness
5.4%
2/37 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Nervous system disorders
Dysgeusia
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Gastroenteritis
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Herpes Zoster
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Herpes Simplex
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Nasopharyngitis
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Sinusitis
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Upper Respiratory Tract Infection
8.1%
3/37 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Gingival Abscess
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Fungal Skin Infection
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Bronchitis
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Infections and infestations
Viral Infection
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Nasal Congestion
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Rhinitis Allergic
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Sinus Congestion
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal Pain
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Postnasal Drip
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Respiratory, thoracic and mediastinal disorders
Sneezing
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Psychiatric disorders
Anxiety
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Psychiatric disorders
Abnormal Dreams
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Cardiac disorders
Ventricular Extrasystoles
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Ear and labyrinth disorders
Ear Pain
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Ear and labyrinth disorders
Vertigo
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Eye disorders
Conjunctival Haemorrhage
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
General disorders
Asthenia
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
General disorders
Fatigue
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 3 • 14 Jul 2006 thru 27 Jan 2007
General disorders
Pain
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007
Injury, poisoning and procedural complications
Arthropod Bite
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Injury, poisoning and procedural complications
Arthropod Sting
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Injury, poisoning and procedural complications
Soft Tissue Injury
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Injury, poisoning and procedural complications
Skin Laceration
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Blood Glucose Increased
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Blood Cholesterol Increased
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Alanine Aminotransferase Increased
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Aspartate Aminotransferase Increased
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Blood Sodium Decreased
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
1/36 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Investigations
Blood Triglycerides Increased
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Metabolism and nutrition disorders
Anorexia
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
1.4%
1/72 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
Metabolism and nutrition disorders
Hypercholesterolaemia
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Skin and subcutaneous tissue disorders
Rash
2.7%
1/37 • Number of events 1 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/72 • 14 Jul 2006 thru 27 Jan 2007
Vascular disorders
Hypertension
0.00%
0/37 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
0.00%
0/36 • 14 Jul 2006 thru 27 Jan 2007
2.8%
2/72 • Number of events 2 • 14 Jul 2006 thru 27 Jan 2007

Additional Information

Grexan Wulff, Manager Regulatory Affairs

Warner Chilcott

Phone: 973-442-3376

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60